Cerus Corporation — Q1 2012 Form 10-Q Summary
Business context and reporting period
Cerus develops and commercializes the INTERCEPT Blood System, a pathogen-inactivation technology for blood components. Platelet and plasma systems were marketed in Europe, the Commonwealth of Independent States, the Middle East and selected other regions; the red blood cell system remained in development. The filing covers the unaudited three months ended March 31, 2012, compared with the restated three months ended March 31, 2011. As of April 23, 2012, 54.4 million common shares were outstanding.
Financial performance and liquidity
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Total revenue | $8.8 million | $6.6 million | +33% |
| Product revenue | $8.7 million | $6.2 million | +41% |
| Government grants and cooperative agreements | $0.1 million | $0.4 million | -79% |
| Gross profit | $3.3 million | $3.1 million | +6% |
| Gross margin | 37% of product sales | 43% of product sales | Down 6 percentage points |
| Operating loss | $4.6 million | $4.3 million | Loss increased $0.3 million |
| Net loss | $8.8 million | $5.1 million | Loss increased $3.7 million |
| Net loss per share | $0.17 | $0.11 | Loss per share increased |
| Net cash used in operations | $3.9 million | $5.1 million | Use decreased $1.2 million |
Product revenue growth reflected higher sales of platelet and plasma disposable kits to existing customers and new customer adoption. Cost of product revenue increased 56% to $5.5 million, driven by higher volumes and scrap charges. Gross margin declined because of a higher proportion of plasma kits sold and unusable component scrap.
Operating expenses were $7.8 million, including $1.8 million of research and development expense and $6.0 million of selling, general and administrative expense. The larger net loss primarily reflected a $4.5 million non-cash loss from revaluation of warrant liabilities, compared with $1.3 million in Q1 2011. Stock-based compensation expense was $0.5 million.
Cash, cash equivalents and short-term investments totaled $31.5 million at March 31, 2012, compared with $25.8 million at December 31, 2011. Cash increased by $6.0 million during the quarter, principally because of $9.2 million of net proceeds from the sale of approximately 3.0 million shares under the at-the-market offering. Working capital increased to $19.2 million from $18.6 million.
Total debt was $7.2 million, consisting principally of a $5.0 million Comerica growth capital loan and $2.3 million drawn under a revolving line of credit. Debt principal and interest obligations totaled $8.2 million under the filing’s contractual-obligations schedule. The company was in compliance with its debt covenants, including a $2.5 million minimum cash requirement and minimum revenue tests.
Material changes versus the prior comparable period
- Product revenue increased $2.5 million, or 41%, while grant revenue declined $0.3 million, or 79%.
- Product gross margin declined from 43% to 37% because of product mix and higher scrap charges.
- SG&A expense increased 8% to $6.0 million; research and development expense was essentially flat.
- The warrant liability increased from $8.0 million at December 31, 2011 to $12.4 million at March 31, 2012, producing a $4.5 million non-cash revaluation loss.
- Net cash used in operations improved to $3.9 million from $5.1 million, but the company remained dependent on external financing.
- Inventory increased to $8.9 million from $6.4 million, primarily reflecting higher finished goods and work-in-process levels.
- The March 31, 2011 financial information was restated to expense previously capitalized inventory costs as products were sold, reducing inventory and increasing cost of product revenue by approximately $0.1 million.
Guidance, outlook, commentary and risks
Management expected product revenue for the platelet and plasma systems to continue increasing as market acceptance expanded, but cautioned that historical results may not predict future revenue. Research and development spending was expected to increase as the company pursued red blood cell clinical development in Europe and additional U.S. studies.
The company exhausted the remaining availability under its $2.1 million Department of Defense grant by March 31, 2012 and stated that future federal funding was uncertain. Management believed cash from product sales, existing cash and access to debt would fund requirements for at least the next twelve months, while warning that incorrect assumptions or limited access to capital could require reductions in development or commercialization activities.
- The FDA disapproved the proposed IDE supplement for a red blood cell Phase III trial, indicating that at least an additional Phase I recovery and survival study and additional in vitro studies were required before the proposed trial could proceed.
- Additional capital would be required to complete red blood cell development and pursue potential European regulatory approval.
- The company remained loss-making and stated that it might never achieve profitability.
- Fenwal was the sole manufacturer of platelet and plasma disposable kits under an agreement extending through December 31, 2013; supply disruption, manufacturing costs, component shortages and quality issues could affect revenue and margins.
- The business had significant customer concentration: three customers represented approximately 68% of trade receivables at March 31, 2012, and three customers represented 65% of product revenue in the quarter based on disclosed customer percentages.
- Market acceptance depends on regulatory approvals, reimbursement, customer budgets, product efficacy, compatibility with collection platforms and competition.
- The company’s debt was secured by substantially all current and future assets other than intellectual property and 35% of its investment in Cerus Europe B.V.; covenant noncompliance could accelerate repayment.
- Foreign-exchange volatility, product liability, intellectual-property claims, inventory expiration or obsolescence, and earthquake-related business interruption were identified as additional risks.
Most important facts for investors to verify
- Whether product revenue growth continues without comparable government grant support.
- Whether gross margin recovers from the 37% Q1 level and whether scrap and supply-chain costs decline.
- The cash-burn rate, remaining liquidity and need for additional equity or debt financing.
- Compliance with Comerica’s minimum cash and revenue covenants and the timing of required debt repayments.
- Regulatory progress, funding requirements and clinical milestones for the red blood cell system.
- Dependence on Fenwal and other sole-source suppliers, including the status of manufacturing agreements and minimum purchase commitments.
- The potential share dilution from future equity issuance, stock options and approximately 6.1 million outstanding warrant shares.
- The effect of changes in the company’s share price and valuation assumptions on the $12.4 million warrant liability and reported net loss.